Trial Profile

Phase Ib/II Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Mirdametinib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Adverse reactions
Acronyms IMMUNOMEK

14 Feb 2025 Planned End Date changed from 1 Apr 2029 to 25 May 2028.
14 Feb 2025 Planned primary completion date changed from 1 Apr 2029 to 25 May 2028.
14 Feb 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com